Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analysesResearch in context

Summary: Background: We aimed to assess real-world efficacy of the PARP inhibitor, olaparib, in US Veterans with metastatic prostate cancer (mPC) by leveraging the national data repository and evaluate a novel approach to assess treatment efficacy in tumors considered rare or harboring rare mutatio...

Descripció completa

Dades bibliogràfiques

Autors principals:	Harshraj Leuva, Mengxi Zhou, Nader Jamaleddine, Mina Meseha, Izak Faiena, Yeun-Hee Anna Park, Glen McWilliams, Carol Luhrs, Kara N. Maxwell, Daniel Von Hoff, Susan E. Bates, Tito Fojo
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-09-01
Col·lecció:	EBioMedicine
Matèries:	Homologous recombination repair Olaparib Real-world data g-rate Efficacy evaluation Prostate cancer
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2352396424003244
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!